What Is the Best Strategy for Prevention of Postoperative Nausea and Vomiting?


INTRODUCTION

Postoperative nausea and vomiting (PONV) are among the most common side effects associated with anesthesia and surgery. Currently, the overall incidence of PONV for all surgeries and patient populations is estimated to be 25% to 30%. Furthermore, PONV can lead to a delay in postanesthesia care unit (PACU) discharge, unanticipated hospital admission, or both, thereby increasing medical costs. Symptoms of PONV are also among the most unpleasant experiences associated with surgery and one of the most common reasons for poor patient satisfaction ratings in the postoperative period. In one survey, surgical patients were willing to pay up to $100 to avoid PONV. Optimal PONV prophylaxis is also an essential component of enhanced recovery after surgery (ERAS) protocols.

Anesthesia-, patient-, and surgery-related factors associated with increased risk for PONV have been identified ( Table 29.1 ). Apfel et al. developed a simplified risk score consisting of four predictors: female gender, history of motion sickness or PONV, nonsmoking status, and the use of opioids for postoperative analgesia. If none, one, two, three, or four of these risk factors were present, the incidence of PONV was 10%, 21%, 39%, 61%, and 79%, respectively.

TABLE 29.1
Risk Factors for Postoperative Nausea and Vomiting
Anesthetic Factors Patient Factors Surgical Factors
  • 1.

    Volatile agents

  • 2.

    Nitrous oxide

  • 3.

    Opioids

  • 4.

    High doses of neostigmine

  • 1.

    Female gender

  • 2.

    History of PONV or motion sickness

  • 3.

    Pain

  • 4.

    High levels of anxiety

  • 1.

    Long surgical procedures

  • 2.

    Certain types of surgery: intraabdominal; major gynecologic; laparoscopic; breast; ear, nose, and throat; strabismus; intracranial

PONV, Postoperative nausea and vomiting.

THERAPIES

Pharmacologic Agents

Pharmacologic agents available for the prevention of PONV can be summarized as follows:

  • Conventional antiemetics

    • Dopamine (D 2 ) receptor antagonists: phenothiazines (e.g., promethazine, prochlorperazine), butyrophenones (e.g., droperidol, haloperidol), benzamides (e.g., metoclopramide), substituted benzamides (e.g., amisulpride)

    • Antihistamines (e.g., dimenhydrinate, cyclizine)

    • Anticholinergics (e.g., scopolamine)

    • Serotonin receptor antagonists (e.g., ondansetron, granisetron, palonosetron, ramosetron)

    • Neurokinin-1 receptor antagonists (e.g., aprepitant)

  • Nonconventional antiemetics

    • Steroids, propofol

  • Other therapies that might be of benefit

    • Benzodiazepines, ephedrine, gabapentinoids, aggressive intravenous hydration

You're Reading a Preview

Become a Clinical Tree membership for Full access and enjoy Unlimited articles

Become membership

If you are a member. Log in here